LIF shares TLV`s view that these ancillary agreements lead to savings. At the same time, the experience of LIF shows that the incentives for companies to conclude ancillary agreements with regions have been reduced by ancillary agreements with IP clauses. The Swedish legal framework allows for the hiring of health professionals as speakers at scientific meetings, advisory board participants, research or other expert services. The conclusion of written agreements between the health professional, his employer and the company is one of the specific requirements that must be met under the rules of the ERA. In addition, there may be no other benefits, allowances or gifts other than compensation for the corresponding travel, meal and accommodation expenses. A healthcare professional can only be associated with an advisory committee if he can bring expertise in a given area where this expertise is not in the company. He/she may receive appropriate hourly fees or fees corresponding to the time and effort invested in the contract. In order to be able to carry out research on samples covered by Swedish biobance legislation, a biobankonic agreement is required. The legislation includes human biology samples taken as part of health care and medical care and which can be assigned to individual sample providers.
Cooperation between health and pharmaceutical companies is accepted and may have different characteristics and different objectives and purposes. The rules of the LER define the fundamental principles and rules of such cooperation, as well as a detailed framework for so-called development projects, relating to cooperation in the form of projects, covering areas and themes having a natural link with the activities of the Parties. Development projects should not be launched to finance or support normal health activities. With regard to development projects, the rules of the LER require, among other things, that an agreement be concluded to regulate the content and scope of the project. The project should be limited in time and, as a rule, no more than one year. In addition, both health and pharmaceutical companies must contribute to the project with resources such as funding, equipment and working time, and the distribution between the contributions of the parties must be balanced. . . .